GO 8H3
Alternative Names: GO-8H3Latest Information Update: 04 Feb 2021
At a glance
- Originator GO Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer
Most Recent Events
- 22 Jan 2021 Early research in Colorectal cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 22 Jan 2021 Early research in Gastric cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
- 22 Jan 2021 Early research in Liver cancer in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)